Alopecia News

MIAMI BEACH, Fla. — As interest in alternative treatment options grow, a speaker at South Beach Symposium shared her go-to nutrition guidelines for patients suffering from hair loss.

Having asthma, Hashimoto’s thyroiditis or atopic dermatitis in addition to alopecia areata raised the odds for early-onset, severe and prolonged alopecia areata, according to a research letter published in Allergy.

Topical ET-02 demonstrated successful results in its first-in-human clinical trial for the treatment of androgenic alopecia, Eirion Therapeutics announced in a press release.

One in eight women will suffer from breast cancer in their lifetime. Eight percent will decline treatment due to the fear of alopecia.

SARS-CoV-2 infection, especially a severe case or without vaccination, significantly increases the long-term risk for developing autoimmune and autoinflammatory connective tissue diseases, according to data published in JAMA Dermatology.

Major strides have been made in alopecia research in 2024. The FDA’s approval of the oral Janus kinase inhibitor Leqselvi was the most-read alopecia article on Healio this year, with studies about minoxidil and metformin also making the list.

Patients with hair loss disorders often suffer severe mental health effects. While medical intervention has grown in recent years, many individuals still rely on cranial hair prostheses, or wigs, which can be costly.

A combination of topical finasteride and minoxidil was more efficacious than minoxidil alone in the treatment of male pattern androgenic alopecia, according to a study.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio cDermatology Chief Medical Editor, discusses hot topics in the field with leading experts.